Developing differentiated medicines

for devastating diseases including intractable cancers, lymphatic and GI diseases, CNS disorders and inflammatory and immunological diseases

Focus on the Brain Immune Gut (BIG) Axis

23 product candidates

14 are clinical stage

1 FDA cleared product

Relationships with 8 major pharma companies
or their investment arms

 

Team of world-class scientists and industry leaders

Publications
Internal Pipeline
PureTech's Lymphatic Leap
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Vedanta
Science: The Gut’s Clostridium Cocktail
Press releases
2020-06-02
PureTech Founded Entity Gelesis Receives Approval to Market PLENITY™ in Europe as a Weight Loss Treatment

Continue

Press releases
2020-05-28
PureTech Advances LYT-100 (Deupirfenidone) for Treatment of Serious Respiratory Complications that Persist Following Resolution of COVID-19 Infection

Continue

Press releases
2020-05-27
PureTech to Present at Jefferies Virtual Healthcare Conference

Continue